Glycerophosphoinositols (GPIs) and derivatives thereof for use in treating, preventing or reducing the severity of a symptom of sepsis, severe sepsis or septic shock related to a Lipopolysaccharide -activated tissue-factor activity, wherein said symptom comprises a disorder of coagulation and/or a disseminated intravascular coagulation and wherein the glycerophosphoinositol is a compound having the following formula: and the derivatives of glycerophosphoinositols (GPIs) are compounds of general formula: their enantiomers, diastereoisomers, racemes, their mixtures, their hydrates and solvates, wherein: I) R', R2', R2, R3, R4, R5, R6 which can be equal or different among each other, being: a) H or b) a group C A, acylic residue of mono-carboxylic acid or emiacylic residue of dicarboxylic acid, where A can be: a saturated or unsaturated, straight or branched aliphatic radical having from 1 to 4 double bonds, or a mono or poly-cyclic alkyl or alkenyl group, or an aryl, arylalkyl or heterocyclic group having one or more heteroatoms; these groups are optionally substituted with one or more groups selected among keto, hydroxy, acylamido, halogen, mercapto, alkylthio or alkyldithio, -COOH and these -COOH are optionally in the salt form -COOM, wherein M has the same meaning described at point; or c) a group B wherein B is a saturated or unsaturated, straight or branched aliphatic group with from 1 to 6 double bonds, or a mono or poly-cyclic alkyl or alkenyl group or an aryl, alkylaryl group or a heterocycle having one or more heteroatoms; these groups are optionally substituted with one or more groups selected among keto, hydroxy, acylamido, halogen, mercapto, alkylthio or alkyldithio, -COOH and these -COOH are optionally in the salt form - COOM, wherein M has the same meaning described at point; M is the cation of a pharmacologically acceptable inorganic element, or a cation of a pharmacologically acceptable organic base having valence n+ wherein n has the meaning described in the following point; n is 1 or 2 or 3; X e Y equal or different among each other are O or S; and wherein, when Y is S, the compounds according to formula include also the respective not-neutralized compounds. I) R', R2', R2, R3, R4, R5, R6 which can be equal or different among each other, being: a) H or b) a group C A, acylic residue of mono-carboxylic acid or emiacylic residue of dicarboxylic acid, where A can be: a saturated or unsaturated, straight or branched aliphatic radical having from 1 to 4 double bonds, or a mono or poly-cyclic alkyl or alkenyl group, or an aryl, arylalkyl or heterocyclic group having one or more heteroatoms; these groups are optionally substituted with one or more groups selected among keto, hydroxy, acylamido, halogen, mercapto, alkylthio or alkyldithio, -COOH and these -COOH are optionally in the salt form -COOM, wherein M has the same meaning described at point; or c) a group B wherein B is a saturated or unsaturated, straight or branched aliphatic group with from 1 to 6 double bonds, or a mono or poly-cyclic alkyl or alkenyl group or an aryl, alkylaryl group or a heterocycle having one or more heteroatoms; these groups are optionally substituted with one or more groups selected among keto, hydroxy, acylamido, halogen, mercapto, alkylthio or alkyldithio, -COOH and these -COOH are optionally in the salt form - COOM, wherein M has the same meaning described at point; a) H or b) a group C A, acylic residue of mono-carboxylic acid or emiacylic residue of dicarboxylic acid, where A can be: a saturated or unsaturated, straight or branched aliphatic radical having from 1 to 4 double bonds, or a mono or poly-cyclic alkyl or alkenyl group, or an aryl, arylalkyl or heterocyclic group having one or more heteroatoms; these groups are optionally substituted with one or more groups selected among keto, hydroxy, acylamido, halogen, mercapto, alkylthio or alkyldithio, -COOH and these -COOH are optionally in the salt form -COOM, wherein M has the same meaning described at point; or c) a group B wherein B is a saturated or unsaturated, straight or branched aliphatic group with from 1 to 6 double bonds, or a mono or poly-cyclic alkyl or alkenyl group or an aryl, alkylaryl group or a heterocycle having one or more heteroatoms; these groups are optionally substituted with one or more groups selected among keto, hydroxy, acylamido, halogen, mercapto, alkylthio or alkyldithio, -COOH and these -COOH are optionally in the salt form - COOM, wherein M has the same meaning described at point; M is the cation of a pharmacologically acceptable inorganic element, or a cation of a pharmacologically acceptable organic base having valence n+ wherein n has the meaning described in the following point; n is 1 or 2 or 3; X e Y equal or different among each other are O or S;